GlassScriptPhysician profile
Anthony Charles Simchak
NPI 1639176530
$719,781.14
in general payments reported to CMS, 2019-2025
54 companies · $105K in 2025
The $105K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166K · 2020: $121K · 2021: $117K · 2022: $111K · 2023: $37K · 2024: $64K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $144K · Consulting Fee: $25K · Honoraria: $17K · Travel and Lodging: $12K · Food and Beverage: $7,550 · Education: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $143,800.00 |
| Consulting Fee | $24,780.00 |
| Honoraria | $16,590.00 |
| Travel and Lodging | $11,761.04 |
| Food and Beverage | $7,550.05 |
| Education | $1,335.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $209,474.24 | 2019-2025 | Ingrezza |
| Abbvie INC. | $169,561.69 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $100,416.16 | 2019-2022 | |
| Amgen INC. | $80,623.96 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $43,790.72 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $31,561.19 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $19,796.19 | 2020-2021 | |
| Axsome Therapeutics, INC. | $14,861.97 | 2025 | Symbravo |
| Kyowa Kirin, INC. | $11,953.19 | 2020-2021 | |
| Lundbeck LLC | $7,194.09 | 2019-2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $7,040.05 | 2022 | |
| Amneal Pharmaceuticals LLC | $4,887.67 | 2022-2024 | Ongentys, Ongentys 50mg Capsules 30 |
| Eisai INC. | $4,137.07 | 2022-2023 | |
| Medtronic USA, INC. | $2,146.37 | 2019 | |
| Pfizer INC. | $1,786.81 | 2019-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,639.26 | 2019-2021 | |
| Genentech USA, INC. | $1,484.32 | 2019-2022 | |
| Ucb, INC. | $938.51 | 2019-2025 | Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $887.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $876.95 | 2019-2025 | |
| Genzyme Corporation | $668.07 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $541.74 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $459.60 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Livanova USA, INC. | $392.99 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Promius Pharma LLC | $388.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $366.96 | 2021 | |
| Tg Therapeutics, INC. | $295.98 | 2024-2025 | |
| Horizon Therapeutics Plc | $279.43 | 2022-2023 | Uplizna |
| Acorda Therapeutics, INC | $156.72 | 2019-2021 | |
| Grt US Holding, INC. | $128.76 | 2021 | |
| Emd Serono, INC. | $126.85 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $112.78 | 2019-2021 | |
| Boston Scientific Corporation | $93.97 | 2020-2024 | |
| Exact Sciences Corporation | $91.73 | 2023-2025 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $78.23 | 2024 | |
| Upsher-Smith Laboratories LLC | $58.84 | 2020-2021 | |
| Medtronic, INC. | $57.81 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $47.11 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $45.08 | 2019-2020 | |
| Novo Nordisk INC | $37.06 | 2020-2021 | |
| Biogen, INC. | $29.85 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Alexion Pharmaceuticals, INC. | $29.14 | 2019 | |
| Grifols USA, LLC | $27.76 | 2023 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $27.12 | 2023 | Inspire |
| Celgene Corporation | $24.16 | 2021 | |
| Vertical Pharmaceuticals, LLC | $18.25 | 2019 | |
| Abbott Laboratories | $18.16 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $17.62 | 2020 | |
| Insulet Corporation | $16.13 | 2023 | Omnipod |
| Dexcom, INC. | $15.97 | 2021 | |
| Csl Behring | $15.43 | 2019 | |
| Tanabe Pharma America, INC. | $13.62 | 2021 | |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Simchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.